Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus in Advanced Cancer with PI3K Mutation or PTEN Loss
NCT00877773Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2009
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temsirolimus in cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2009; status: terminated.
02
Drugs
temsirolimus
03
Conditions
cancer
Beyond the preview
Go deeper on NCT00877773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00877773.